Data / Form D filings / Kaida BioPharma Inc.
Kaida BioPharma Inc.: Form D filings
Kaida BioPharma Inc., a biotechnology company in Fort Lauderdale, FL, filed 3 Form D notices with the SEC between 2023 and 2026. The latest, on September 1, 2026, reports $1.6 million sold of a $4.1 million offering to 44 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 416 SW 1ST AVENUE SUITE 101, Fort Lauderdale, FL, 33301
- Phone
- (917) 683-3092
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2022
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1973954
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Amendment | $4,100,507 | $1,600,507 | $2,500,000 | 44 | Oct 24, 2023 | sec.gov |
| Jan 21, 2026 | New notice | $3,000,000 | $1,570,507 | $1,429,493 | 42 | Oct 24, 2023 | sec.gov |
| Jun 14, 2023 | New notice | $4,020 | $4,020 | 47 | Jun 1, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Craig Pierson | Executive Officer, Director | President |
| Stella Vnook | Director | |
| Richard Warburg | Director |
Other biotechnology companies in Florida that filed recently
- AdhereBio LLC offering · Oct 26, 2026
- Ascoltare Holdings LLC $1.7 million · Oct 23, 2026
- Immorta Bio, Inc. $612,503 · Oct 16, 2026
- CURADEL SURGICAL INNOVATIONS, INC. $49.8 million · Oct 13, 2026
- BioStem Technologies, Inc. $3 million · Oct 9, 2026
- HCW Biologics Inc. $1.5 million · Oct 8, 2026
Every Form D from the week of Aug 31, 2026 · All recent filings in Florida · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Kaida BioPharma Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.